OncoCilAir - Oncotheis

Document technical information

Format pdf
Size 864.7 kB
First found May 22, 2018

Document content analysis

Category Also themed
Language
English
Type
not defined
Concepts
no text concepts found

Persons

Organizations

Places

Transcript

OncoCilAir
TM
Human 3D in vitro lung cancer model
Figure 1: Histological section (H&E) of an OncoCilAir™ culture showing a tumor nodule invading the
surrounding healthy human airway epithelium.
100% human
Airway + Tumor + Stroma
Direct fluorescence read-out
Ready to use
Lung cancer, an unmet medical need
With more than 1 million deaths worldwide every year, lung cancer remains an area of unmet need. To date there
is no effective treatment for patients and unfortunately, a large number of promising drug leads keep failing in
late clinical stages. These observations have cast uncertainty on the established drug discovery process and
question the relevancy of the animal models currently in use. Accessible human in vitro 3D tissue models are
required to improve preclinical predictivity.
Modelling the disease
Maintaining a 3D environment is critical for cell-cell interaction and ultimately for the
proper development of human cancer. At OncoTheis, we have used our expertise in tissue
engineering to build up a novel three-dimensional lung cancer model, OncoCilAir™, which
integrates three different human components: bronchial cells, lung fibroblasts and Non
Small Cell Lung Carcinoma cells.
Because of its unique design, OncoCilAir™ closely mimics in vitro human tumors invading
the adjacent 3D normal airway epithelium (Figure 1). Indeed, by contrast to cells grown
under 2D culture conditions, OncoCilAir™ tumors extend by forming nodules, a hallmark of
human lung cancer (Figure 2). This property makes OncoCilAir™ an ideal model to
accurately explore the tumor response to therapeutic agents in a relevant biomimetic
context.
Figure
2:
OncoCilAir™
cultures closely mimic the
characteristic tumor lung
nodules found in patients.
Applications
o
o
o
o
o
o
o
o
o
Compound efficacy studies (Figure 3)
Accute and chronic toxicity
Therapeutic antibodies testing
Nano-cancer therapies testing
Oncolytic virus therapies testing
Drug delivery (airway/systemic)
Predictive biomarkers
Cytokines, chemokines, metalloproteinases release
Tumor resistance and relapse
For more details, please contact us at
[email protected]
OncoTheis
14, Chemin des aulx
CH-1228 Plan les Ouates
www.oncotheis.com
mut
Figure 3: Tumor growth in OncoCilAir™ KRAS cultures is inhibited by
MEK (selumetinib) but not EGFR-TK (erlotinib) inhibitors.
Contact: Samuel Constant, PhD, CEO
Phone: +41 22 795 65 16
Email: [email protected]
All rights reserved
© 2014 OncoTheis
OncoCilAir
TM
Human 3D in vitro lung cancer model
Ciliated
Tumor
Goblet Cells
Basal cells
Human Fibroblasts
Process Overview
Reference: Mas C et al. Journal of Biotechnology 2015, in press
Test OncoCilAir™, free samples available on request
Please contact us at [email protected]
OncoTheis
14, Chemin des aulx
CH-1228 Plan les Ouates
www.oncotheis.com
Contact: Samuel Constant, PhD, CEO
Phone: +41 22 795 65 16
Email: [email protected]
All rights reserved
© 2014 OncoTheis
×

Report this document